InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals is a Swedish pharma company founded in 2000 at the Karolinska Institutet Science Park in Stockholm. Specialized in developing therapies for immunological diseases, mainly ulcerative colitis with cobitolimod. Also developed DiBiCol, a diagnostic test for IBD approved in Sweden in 2009. In February 2024 announced discontinuation of cobitolimod development and is evaluating strategic options.